Please use this identifier to cite or link to this item:
|Title:||Intragastric administration of Lactobacillus casei expressing transmissible gastroentritis coronavirus spike glycoprotein induced specific antibody production||Authors:||Ho, P.S.
|Issue Date:||3-Feb-2005||Citation:||Ho, P.S., Kwang, J., Lee, Y.K. (2005-02-03). Intragastric administration of Lactobacillus casei expressing transmissible gastroentritis coronavirus spike glycoprotein induced specific antibody production. Vaccine 23 (11) : 1335-1342. ScholarBank@NUS Repository. https://doi.org/10.1016/j.vaccine.2004.09.015||Abstract:||Lactobacillus casei strain Shirota was selected as a bacterial carrier for the development of live mucosal vaccines against coronavirus. A 75 kDa fragment of transmissible gastroenteritis coronavirus (TGEV) spike glycoprotein S was used as the model coronavirus antigen. The S glycoprotein was cloned into a Lactobacillus/E. coli shuttle vector (pLP500) where expression and secretion of the glycoprotein S from the recombinant lactobacilli was detected via immunoblotting. Oral immunization of BALB/c mice with recombinant LcS that constitutively expresses the 75 kDa fragment of the glycoprotein S, induced both local mucosal and systemic immune responses against TGEV. Maximum titers of IgG (8.38 ± 0.19 ng/ml of serum) and IgA (64.82 ± 2.9 ng/ml of intestinal water) were attained 32 days post oral inturbation. The induced antibodies demonstrated neutralizing effects on TGEV infection. © 2004 Elsevier Ltd. All rights reserved.||Source Title:||Vaccine||URI:||http://scholarbank.nus.edu.sg/handle/10635/131546||ISSN:||0264410X||DOI:||10.1016/j.vaccine.2004.09.015|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Oct 16, 2020
WEB OF SCIENCETM
checked on Oct 8, 2020
checked on Oct 17, 2020
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.